Therefore, using MCL1 inhibitors in combination with ICIs for these cancers may improve outcomes and kill cancer cells, through the MCL1 inhibitor’s direct killing effects on tumor cells and indirect effects on MDSCs. This evidence concerns the gene MCL1 and cancer.